Biochemical Engineering
UK cost watchdog recommends Novartis' blindness therapy Luxturna
4th September 2019
Novartis AG’s gene therapy for blindness, Luxturna, is recommended for use on England’s public health service, the country’s healthcare cost-effectiveness watchdog NICE said on Tuesday. Novartis owns the rights to sell the one-time gene therapy developed by Spark Therapeutics outside the United States. Source: Reuters 4/9/2019
Back to group news